Cover Image
市場調查報告書

頭頸癌:開發中產品分析

Head And Neck Cancer - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 351248
出版日期 內容資訊 英文 1247 Pages
訂單完成後即時交付
價格
Back to Top
頭頸癌:開發中產品分析 Head And Neck Cancer - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 1247 Pages
簡介

頭頸癌是在頭部或頸部(鼻腔,副鼻腔,嘴唇,口,唾液腺,喉嚨或喉)等領域發生的癌症。這個癌症的一般症狀有喉嚨的持續性疼痛,伴隨吞嚥的疼痛和困難,持續性的嘶啞聲和聲音變化,耳朵的疼痛,口內和喉嚨出血等。可用化療和放射治療管理。

本報告提供頭頸癌的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

頭頸癌概要

治療藥的開發

頭頸癌:治療藥的評估

頭頸癌治療藥的開發企業

藥物簡介

頭頸癌:暫停中的計劃

頭頸癌:開發中止的產品

頭頸癌:產品開發的里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9282IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer - Pipeline Review, H1 2017, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.

Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 87, 98, 5, 92, 17 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 11, 6, 1, 15 and 3 molecules, respectively.

Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Head And Neck Cancer - Overview
  • Head And Neck Cancer - Therapeutics Development
  • Head And Neck Cancer - Therapeutics Assessment
  • Head And Neck Cancer - Companies Involved in Therapeutics Development
  • Head And Neck Cancer - Drug Profiles
  • Head And Neck Cancer - Dormant Projects
  • Head And Neck Cancer - Discontinued Products
  • Head And Neck Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Head And Neck Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..17), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..18), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..19), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Head And Neck Cancer - Pipeline by 3SBio Inc, H1 2017
  • Head And Neck Cancer - Pipeline by 4SC AG, H1 2017
  • Head And Neck Cancer - Pipeline by AB Science SA, H1 2017
  • Head And Neck Cancer - Pipeline by AbbVie Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Abion Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Accelerated Pharma Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Acceleron Pharma Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
  • Head And Neck Cancer - Pipeline by Aduro BioTech Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Advaxis Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Head And Neck Cancer - Pipeline by Affimed GmbH, H1 2017
  • Head And Neck Cancer - Pipeline by Altor BioScience Corp, H1 2017
  • Head And Neck Cancer - Pipeline by Ambrx Inc, H1 2017
  • Head And Neck Cancer - Pipeline by amcure GmbH, H1 2017
  • Head And Neck Cancer - Pipeline by Amgen Inc, H1 2017
  • Head And Neck Cancer - Pipeline by arGEN-X BV, H1 2017
  • Head And Neck Cancer - Pipeline by ArQule Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Array BioPharma Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Aspyrian Therapeutics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Astellas Pharma Inc, H1 2017
  • Head And Neck Cancer - Pipeline by AstraZeneca Plc, H1 2017
  • Head And Neck Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by ATLAB Pharma SAS, H1 2017
  • Head And Neck Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Bayer AG, H1 2017
  • Head And Neck Cancer - Pipeline by BeiGene Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Benitec Biopharma Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Beta Pharma Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
  • Head And Neck Cancer - Pipeline by BioDiem Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Bionovis SA, H1 2017
  • Head And Neck Cancer - Pipeline by BioNTech AG, H1 2017
  • Head And Neck Cancer - Pipeline by Biotest AG, H1 2017
  • Head And Neck Cancer - Pipeline by Biothera Pharmaceutical Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Head And Neck Cancer - Pipeline by Boston Biomedical Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Head And Neck Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Celgene Corp, H1 2017
  • Head And Neck Cancer - Pipeline by Cell Medica Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Cellceutix Corp, H1 2017
  • Head And Neck Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Celprogen Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Centrose LLC, H1 2017
  • Head And Neck Cancer - Pipeline by Corvus Pharmaceuticals Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Cristal Therapeutics BV, H1 2017
  • Head And Neck Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
  • Head And Neck Cancer - Pipeline by CytImmune Sciences Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Denceptor Therapeutics Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by DNJ Pharma Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Dynavax Technologies Corp, H1 2017
  • Head And Neck Cancer - Pipeline by Eisai Co Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Eleven Biotherapeutics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Eli Lilly and Company, H1 2017
  • Head And Neck Cancer - Pipeline by Etubics Corp, H1 2017
  • Head And Neck Cancer - Pipeline by Eureka Therapeutics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Five Prime Therapeutics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Forty Seven Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Fujifilm Corp, H1 2017
  • Head And Neck Cancer - Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Galectin Therapeutics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Genelux Corp, H1 2017
  • Head And Neck Cancer - Pipeline by GeneSegues Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Genexine Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Genmab A/S, H1 2017
  • Head And Neck Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Head And Neck Cancer - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Gliknik Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Glycotope GmbH, H1 2017
  • Head And Neck Cancer - Pipeline by Griffith University, H1 2017
  • Head And Neck Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Hookipa Biotech AG, H1 2017
  • Head And Neck Cancer - Pipeline by Horizon Pharma Plc, H1 2017
  • Head And Neck Cancer - Pipeline by Hutchison China MediTech Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Ignyta Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Immunocore Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Immunomedics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Immunovaccine Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Immunovative Therapies Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Incyte Corp, H1 2017
  • Head And Neck Cancer - Pipeline by Infinity Pharmaceuticals Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Innate Pharma SA, H1 2017
  • Head And Neck Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Head And Neck Cancer - Pipeline by InteRNA Technologies BV, H1 2017
  • Head And Neck Cancer - Pipeline by Ipsen SA, H1 2017
  • Head And Neck Cancer - Pipeline by IRX Therapeutics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2017
  • Head And Neck Cancer - Pipeline by ISU ABXIS Co Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Johnson & Johnson, H1 2017
  • Head And Neck Cancer - Pipeline by Juno Therapeutics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Kite Pharma Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Kura Oncology Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Laboratoires Pierre Fabre SA, H1 2017
  • Head And Neck Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Loxo Oncology Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Lytix Biopharma AS, H1 2017
  • Head And Neck Cancer - Pipeline by Mabion SA, H1 2017
  • Head And Neck Cancer - Pipeline by MacroGenics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Marsala Biotech Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Mateon Therapeutics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by MaxiVAX SA, H1 2017
  • Head And Neck Cancer - Pipeline by Meabco A/S, H1 2017
  • Head And Neck Cancer - Pipeline by MedImmune LLC, H1 2017
  • Head And Neck Cancer - Pipeline by Merck & Co Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Merck KGaA, H1 2017
  • Head And Neck Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Mirati Therapeutics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Moleculin Biotech Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Molplex Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by NanoCarrier Co Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by NantKwest Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Natco Pharma Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by NeoImmuneTech Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Neonc Technologies Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Neumedicines Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Northwest Biotherapeutics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Novartis AG, H1 2017
  • Head And Neck Cancer - Pipeline by Noxopharm Ltd, H1 2017
  • Head And Neck Cancer - Pipeline by Oncobiologics Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Oncolys BioPharma Inc, H1 2017
  • Head And Neck Cancer - Pipeline by Onconova Therapeutics Inc, H1 2017

List of Figures

  • Number of Products under Development for Head And Neck Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top